

Table A1. Checkmate 649 results from original subgroup analysis by PD-L1 CPS^{23,55}

Population	Nivolumab + chemotherapy	Chemotherapy alone	Unstratified HR (95% CI)	Interactive p value*
Median overall survival (months)				
Overall (n = 1581)	13.8	11.6	0.79 (0.70-0.89)	NR
PD-L1 CPS < 1 (n = 265)	13.1	12.5	0.92 (0.70-1.23)	NS
PD-L1 CPS ≥ 1 (n = 1296)	14.0	11.3	0.76 (0.67-0.87)	0.2041
PD-L1 CPS < 5 (n = 606)	12.4	12.3	0.94 (0.78-1.13)	NS
PD-L1 CPS ≥ 5 (n = 955)	14.4	11.1	0.70 (0.60-0.81)	0.0107*
Median progression free survival (months)				
Overall (n = 1581)	7.7	6.9	0.77 (0.68-0.87)	NR
PD-L1 CPS < 1 (n = 265)	8.7	8.1	0.93 (0.69-1.26)	NS
PD-L1 CPS ≥ 1 (n = 1296)	7.5	6.9	0.75 (0.65-0.85)	0.1391*
PD-L1 CPS < 5 (n = 606)	7.5	8.2	0.93 (0.76-1.12)	NS
PD-L1 CPS ≥ 5 (n = 955)	7.7	6.1	0.69 (0.59-0.80)	0.0073*
Objective response rate (%)				
Overall (n = 1211)	58	46	12 (6-17.5)	NR
PD-L1 CPS < 1 (n = 178)	51	41	9 (-5 to 23)	NR
PD-L1 CPS ≥ 1 (n = 1019)	60	46	13 (7 – 19)	NR
PD-L1 CPS < 5 (n = 428)	55	46	9 (-0.6 – 18)	NR
PD-L1 CPS ≥ 5 (n = 769)	60	45	15 (7.5 – 21)	NR

CI: confidence interval; HR: hazard ratio; NR: not recorded; NS: not significant

*Significance level for interactive p value was predefined at 0.2

The median follow-up for OS in the original analysis was 13.1 months (interquartile range [IQR] 6.7 19.1) for nivolumab plus chemotherapy and 11.1 months (IQR 5.8 16.1) for chemotherapy alone. The median treatment duration was 6.8 months (IQR 3.7 13.3) with nivolumab plus chemotherapy and 4.9 months (IQR 2.5 8.4) with chemotherapy alone.